Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iSpecimen (ISPC) Other Operating Expenses (2020 - 2025)

Historic Other Operating Expenses for iSpecimen (ISPC) over the last 6 years, with Q3 2025 value amounting to $1.5 million.

  • iSpecimen's Other Operating Expenses fell 4405.49% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year decrease of 2536.77%. This contributed to the annual value of $12.4 million for FY2024, which is 712.4% up from last year.
  • iSpecimen's Other Operating Expenses amounted to $1.5 million in Q3 2025, which was down 4405.49% from $1.0 million recorded in Q2 2025.
  • iSpecimen's 5-year Other Operating Expenses high stood at $4.3 million for Q4 2024, and its period low was $1.0 million during Q2 2025.
  • In the last 5 years, iSpecimen's Other Operating Expenses had a median value of $2.6 million in 2023 and averaged $2.5 million.
  • Its Other Operating Expenses has fluctuated over the past 5 years, first surged by 11498.78% in 2021, then plummeted by 6589.15% in 2025.
  • Quarter analysis of 5 years shows iSpecimen's Other Operating Expenses stood at $2.6 million in 2021, then grew by 19.48% to $3.1 million in 2022, then grew by 0.49% to $3.1 million in 2023, then surged by 41.88% to $4.3 million in 2024, then plummeted by 65.01% to $1.5 million in 2025.
  • Its last three reported values are $1.5 million in Q3 2025, $1.0 million for Q2 2025, and $1.4 million during Q1 2025.